Y Ogawa

No ORCID on file · 6 papers in corpus
article 2012

We report a case of vesical endometriosis that worsened during the early pregnancy period. A 37-yearold woman had been under treatment for endometriosis (including vesical endometriosis) by a gynecologist during the past 10 years. She was t…

article 2010

We report a case of vesical endometriosis that worsened during the early pregnancy period. A 37-year old woman had been under treatment for endometriosis (including vesical endometriosis) by a gynecologist during the past 10 years. She was …

article 1998
Nihon rinsho. Japanese journal of clinical medicine

Monolithic microcapsules were designed and developed for controlled release of leuprorelin for one month following a single injection. Copoly (DL-lactic/glycolic) acid (PLGA) of copolymer ratio of 75/25 and average molecular weight of 14,00…

review 1991
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan ·doi:10.1248/yakushi1947.111.8_397

Leuprorelin (leuprolide, D-Leu6-(des-Gly10-NH2)-LH-RH ethylamide) acetate is a super-active agonist of luteinizing hormone-releasing hormone (LH-RH). We developed once-a-month injectable microcapsules of this agonist by our novel in-water d…

other 1989
Osaka city medical journal

An immunohistochemical study was performed on the localization of carbonic anhydrase isozymes I and II (CA I and CA II, respectively) in oncocytoma and oncocytic epithelial cells. Tumors examined were those deserved to be called oncocytomas…

article 1988
The Journal of pharmacology and experimental therapeutics ·doi:10.1016/s0022-3565(25)24466-4

Leuprolide acetate is a highly potent analog of luteinizing hormone-releasing hormone. We have prepared 1-month release injectable microcapsules of leuprolide acetate using a biodegradable polymer, poly (dl-lactide-co-glycolide), to treat a…